A Case of DRESS Syndrome Associated with Piperacillin-Tazobactam Treatment and Literature Review

A 47-year-old type-2 diabetic male patient was hospitalized with diabetic foot infection, and piperacillin-tazobactam treatment was initiated. In the 3rd week of treatment, fever, malaise, myalgia, leukopenia, eosinophilia, and elevations of transaminases and acute phase reactants developed. Cultures remained sterile, and symptoms regressed with a change of medication and steroid administration. The clinical situation was accepted as “drug rash with eosinophilia and systemic symptoms” (DRESS) syndrome, which is discussed in detail

Current and Future Therapies for Hepatitis C Virus Infection

To the Editor: In their review of drug therapy for chronic hepatitis C infection, Liang and Ghany (May 16 issue)(1) summarize boceprevir- and telaprevir-based regimens. Figure 2 of the article describes the regimens according to the response to the previous therapy, the response-guided therapy, and the stopping rules. The boceprevir regimen they describe represents the labeling information in the United States.(2) However, the information about boceprevir in European regimens has some differences(3) the duration of therapy for patients who have not had a response to previous therapy (whether the patient had a relapse, a partial response, or no response) ..